Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease.
Curr Opin Nephrol Hypertens
; 33(5): 494-502, 2024 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-38899951
ABSTRACT
PURPOSE OF REVIEW Pulmonary hypertension is a common comorbidity in patients with chronic kidney disease (CKD), but therapeutic options are limited. We discuss the epidemiology of pulmonary hypertension in patients with CKD and review therapies for pulmonary hypertension with a focus on emerging treatments for pulmonary arterial hypertension (PAH). RECENT FINDINGS:
The definition of pulmonary hypertension has been updated to a lower threshold of mean pulmonary artery pressures of more than 20âmmHg, potentially leading to more patients with CKD to qualify for the diagnosis of pulmonary hypertension. Endothelin receptor antagonists, a class of medications, which demonstrated efficacy in patients with PAH, have been shown to slow progression of CKD, but their efficacy in lowering pulmonary artery pressures and their effects on reducing cardiovascular mortality in this population remains unproven. Sotatercept, a novel activin signaling inhibitor, which was previously studied in dialysis patients has been shown to increase exercise capacity in patients with PAH. These studies may lead to new specific therapies for pulmonary hypertension in patients with CKD.SUMMARY:
Pulmonary hypertension is common in patients with CKD. Although our understanding of factors leading to pulmonary hypertension in this population have evolved, evidence supporting disease-specific therapy in CKD is limited arguing for larger, long-term studies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Insuficiência Renal Crônica
/
Hipertensão Pulmonar
/
Anti-Hipertensivos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Nephrol Hypertens
Assunto da revista:
ANGIOLOGIA
/
NEFROLOGIA
Ano de publicação:
2024
Tipo de documento:
Article